Comparison of warfarin dosage fluctuation with time in therapeutic range for bleeding or thromboembolism rate in Chinese patients

被引:7
作者
Yu, Hsi-Yu [1 ,2 ]
Tsai, Hsiao-En [3 ]
Chen, Yih-Sharng [1 ,2 ]
Hung, Kuan-Yu [2 ,4 ,5 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Surg, Hsin Chu Branch, Hsin Chu City, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsin Chu City, Taiwan
关键词
Warfarin; Warfarin dosage fluctuation; International normalized ratio; Bleeding; Thromboembolism; NONVALVULAR ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; JAPANESE PATIENTS; RISK-FACTORS; MANAGEMENT; INTENSITY; QUALITY; ADHERENCE; COUNTRIES; CENTERS;
D O I
10.1016/j.jfma.2018.07.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose: Warfarin treatment benefits vary with the clinical skill of warfarin dosage adjustment. However, optimal dosage adjustment in response to the out-of-range international normalized ratio (INR) is not completely understood. Methods: Data for 2014-2016 from an integrated health care information system of a single hospital were analyzed. Based on their warfarin dosage fluctuation (WDF), defined as the standard deviation of all prescribed warfarin dosages divided by the mean dosage, the patients were classified into Groups 1 (0-0.10), 2 (0.10-0.20), and 3 (>0.20). Target and in-range INRs were 2.0-2.5 and 1.5-3.0, respectively. Based on time in therapeutic range (TTR), patients were also categorized into Groups 1 (<0.6), 2 (0.6-0.9), and 3 (>0.9). The primary outcome was emergency department visits for bleeding or thromboembolism (TE) events. Results: Eighty-three events were retrieved from 17,397 records (1834 patients). Annual incidence rates were 0.9%, 2.5%, and 4.5% for WDF Groups 1, 2, and 3, respectively (p < 0.05), and 2.3%, 1.7%, and 1.7% for TTR Groups 1, 2, and 3, respectively (p = 0.41). Area under the receiver operator characteristic curves for WDF and TTR were 0.686 and 0.519, respectively, indicating that WDF exhibited superior predictive performance than TTR. Conclusion: High WDF rather than low TTR was associated with increased bleeding and TE incidence rates. Copyright (C) 2018, Formosan Medical Association. Published by Elsevier Taiwan LLC.
引用
收藏
页码:611 / 618
页数:8
相关论文
共 50 条
  • [21] Patients' time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic
    Lee, Siew Ling
    Ong, Thien Jian
    Mazlan-Kepli, Wardati
    Mageswaran, Annuysia
    Tan, Kai Hsin
    Abd-Malek, Abdul-Muizz
    Cronshaw, Robert
    WORLD JOURNAL OF CARDIOLOGY, 2021, 13 (09): : 483 - 492
  • [22] The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study
    Kilic, Salih
    Celik, Ahmet
    Cakmak, Huseyin Altug
    Afsin, Abdulmecit
    Tekkesin, Ahmet Ilker
    Aciksari, Gonul
    Memetoglu, Mehmet Erdem
    Karadeniz, Fatma Ozpamuk
    Sahan, Ekrem
    Alici, Mehmet Hayri
    Dereli, Yuksel
    Sinan, Umit Yasar
    Zoghi, Mehdi
    BALKAN MEDICAL JOURNAL, 2017, 34 (04) : 349 - 355
  • [23] Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin
    Beton, Osman
    Asarcikli, Lale Dinc
    Sen, Taner
    Ipek, Esra Gucuk
    Kafes, Habibe
    Yaman, Mehmet
    Efe, Tolga Han
    Kaya, Hakki
    Temizhan, Ahmet
    Yilmaz, Mehmet Birhan
    PHARMACOLOGY, 2017, 99 (1-2) : 19 - 26
  • [24] The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
    Celik, Ahmet
    Izci, Servet
    Kobat, Mehmet Ali
    Ates, Ahmet Hakan
    Cakmak, Abdulkadir
    Cakilli, Yasin
    Yilmaz, Mehmet Birhan
    Zoghi, Mehdi
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2016, 16 (08) : 595 - 600
  • [25] Improvement of time in therapeutic range with warfarin by pharmaceutical intervention
    Alvaro Víquez-Jaikel
    Allan Victoria Hall-Ramírez
    International Journal of Clinical Pharmacy, 2017, 39 : 41 - 44
  • [26] Bleeding events with dabigatran or warfarin in patients with venous thromboembolism
    Majeed, Ammar
    Goldhaber, Samuel Z.
    Kakkar, Ajay
    Kearon, Clive
    Eriksson, Henry
    Kreuzer, Joerg
    Feuring, Martin
    Hantel, Stephan
    Friedman, Jeffrey
    Schellong, Sebastian
    Schulman, Sam
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (02) : 291 - 298
  • [28] Time-in-therapeutic range falls as the target international normalized ratio range increases in patients on warfarin
    Malik, Imran
    Priest, Paul
    Jennings, Ian
    Gomez, Keith
    BLOOD COAGULATION & FIBRINOLYSIS, 2025, 36 (03) : 78 - 81
  • [29] Efficacy and safety of apixaban compared with warfarin regarding time within the therapeutic range
    Havasi Kalman
    ORVOSI HETILAP, 2014, 155 (05) : 177 - 181
  • [30] Analysis of factors affecting time in therapeutic range control after warfarin administration
    Kose, E.
    Arai, S.
    An, T.
    Kikkawa, A.
    Aoyama, T.
    Matsumoto, Y.
    Hayashi, H.
    PHARMAZIE, 2015, 70 (07): : 494 - 498